Magle Chemoswed Holding Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Magle Chemoswed Holding has been growing earnings at an average annual rate of 28.5%, while the Life Sciences industry saw earnings growing at 28.5% annually. Revenues have been growing at an average rate of 7.2% per year. Magle Chemoswed Holding's return on equity is 3.4%, and it has net margins of 8%.
Anahtar bilgiler
28.5%
Kazanç büyüme oranı
22.7%
EPS büyüme oranı
| Life Sciences Sektör Büyümesi | 31.8% |
| Gelir büyüme oranı | 7.2% |
| Özkaynak getirisi | 3.4% |
| Net Marj | 8.0% |
| Sonraki Kazanç Güncellemesi | 26 Feb 2025 |
Yakın geçmiş performans güncellemeleri
Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem
Nov 04
Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Recent updates
Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem
Nov 04Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
Oct 05Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?
Jan 22Gelir ve Gider Dağılımı
Magle Chemoswed Holding nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 209 | 17 | 155 | 0 |
| 30 Jun 24 | 179 | 8 | 138 | 0 |
| 31 Mar 24 | 171 | 12 | 132 | 0 |
| 31 Dec 23 | 171 | 12 | 131 | 0 |
| 30 Sep 23 | 160 | 8 | 124 | 0 |
| 30 Jun 23 | 158 | 9 | 121 | 0 |
| 31 Mar 23 | 155 | 8 | 120 | 0 |
| 31 Dec 22 | 148 | 9 | 113 | 0 |
| 30 Sep 22 | 138 | 10 | 106 | 0 |
| 30 Jun 22 | 136 | 10 | 108 | 0 |
| 31 Mar 22 | 133 | 7 | 106 | 0 |
| 31 Dec 21 | 132 | 4 | 106 | 0 |
| 30 Sep 21 | 137 | 3 | 105 | 0 |
| 30 Jun 21 | 133 | 1 | 99 | 0 |
| 31 Mar 21 | 134 | 2 | 99 | 0 |
| 31 Dec 20 | 142 | 2 | 100 | 0 |
| 30 Sep 20 | 151 | 14 | 103 | 0 |
| 30 Jun 20 | 140 | 8 | 104 | 0 |
| 31 Mar 20 | 137 | 1 | 100 | 0 |
| 31 Dec 19 | 132 | 1 | 96 | 0 |
| 31 Dec 18 | 110 | -3 | 99 | 0 |
Kaliteli Kazançlar: MAGLE has high quality earnings.
Büyüyen Kar Marjı: MAGLE's current net profit margins (8%) are higher than last year (5.1%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MAGLE has become profitable over the past 5 years, growing earnings by 28.5% per year.
Büyüme Hızlandırma: MAGLE's earnings growth over the past year (104.1%) exceeds its 5-year average (28.5% per year).
Kazançlar vs. Sektör: MAGLE earnings growth over the past year (104.1%) exceeded the Life Sciences industry 36%.
Özkaynak Getirisi
Yüksek ROE: MAGLE's Return on Equity (3.4%) is considered low.